Goldman Cuts Fresenius to 'Market Perform'

Analyst Hans Bostrom says the medical product maker's profit warning and weaker second-quarter results are disappointing developments

Goldman Sachs cut Fresenius (FMS ) to market perform from market outperform.

On Tuesday the company posted $0.77 second quarter EPADS on a 4.4% revenue rise. Analyst Hans Bostrom says even after his EPADS reduction on July 23, the company missed his second quarter estimate. More importantly, he says the company cut the 2002 net income guidance by 17%, and guided to a mere high-single-digit or low-double-digit recovery in 2003 net income.

Bostrom considers the profit warning in conjunction with second quarter results to be the most disappointing development at the company during its recent turbulence. He cut his estimates, and now sees $3.16 2002 EPADS, $3.58 for 2003, and $4.11 for 2004. He also expects limited scope for fundamentals to lift the stock over the near term.

Before it's here, it's on the Bloomberg Terminal.